Get the Stockscreener App
1.6094
1.52%
-0.0306
Pacific Biosciences Of California Inc stock is traded at $1.6094, with a volume of 301.20K.
It is down -1.52% in the last 24 hours and up +25.19% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.64
Open:
$1.63
24h Volume:
301.20K
Relative Volume:
0.03
Market Cap:
$481.64M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-1.0729
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
-0.31%
1M Performance:
+25.19%
6M Performance:
+3.53%
1Y Performance:
-21.22%
1-Day Range:
$1.605
$1.64
1-Week Range:
$1.50
$1.71
52-Week Range:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.605 | 462.13M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
125.92 | 220.16B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.67 | 157.03B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
401.81 | 154.21B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.91 | 119.08B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.33 | 46.93B | 5.69B | 4.15B | 623.10M | 6.95 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Is Pacific Biosciences of California (NASDAQ:PACB) A Risky Investment? - simplywall.st
These 10 Stocks are Winning Big - Insider Monkey
Wyckoff Accumulation Phase Possible in Pacific Biosciences of California Inc.Entry Points For Growing Stocks Identified by Models - metal.it
Is it the right time to buy Pacific Biosciences of California Inc. stockBuild a winning investment portfolio - jammulinksnews.com
What is Pacific Biosciences of California Inc. company’s growth strategyMaximize your portfolio’s growth potential - jammulinksnews.com
Is Pacific Biosciences of California Inc. a growth stock or a value stockCapitalize on momentum-driven investment opportunities - jammulinksnews.com
How does Pacific Biosciences of California Inc. generate profit in a changing economyCapitalize on proven trading setups - jammulinksnews.com
Why is Pacific Biosciences of California Inc. stock attracting strong analyst attentionBuild wealth steadily with smart stock selection - jammulinksnews.com
How strong is Pacific Biosciences of California Inc. company’s balance sheetInvest smarter with expert stock recommendations - jammulinksnews.com
What are analysts’ price targets for Pacific Biosciences of California Inc. in the next 12 monthsRealize exceptional returns through smart trading - jammulinksnews.com
Here's Why You Should Add PacBio Stock to Your Portfolio Now - MSN
What makes Pacific Biosciences of California Inc. stock attractive to long term investorsExplosive capital appreciation - jammulinksnews.com
Pacific Biosciences shares rise 1.30% premarket after announcing significant advancement in genomic sequencing. - AInvest
Pacific Biosciences of California Inc. Stock Analysis and ForecastExplosive returns - PrintWeekIndia
PacBio (PACB) Technology Powers Significant Genomic Research in Arab Populations | PACB Stock News - GuruFocus
First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand - Yahoo.co
Publication spotlight: How Kinnex long-read RNA sequencing wins out over Illumina for transcript-level quantification - PacBio
What analysts say about Pacific Biosciences of California Inc. stockExceptional earning trajectories - Autocar Professional
Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Intrinsic Value Is Potentially 41% Above Its Share Price - 富途牛牛
Why PacBio (PACB) Stock Is Up Today - Yahoo Finance
QIAGEN’s New Sequencing Panels Boosts PacBio Expansion - StocksToTrade
Pacific Biosciences: The Shift To Razor-Blade Economics Could Be A Game Changer - Seeking Alpha
PacBio Joins 1000 Genomes Long Read Sequencing Project to Enhance Human Genomics Research - Nasdaq
PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio - Yahoo Finance
Is Pacific Biosciences of California Inc. a good long term investmentPhenomenal wealth increase - Autocar Professional
QIAGEN Expands NGS Portfolio with QIAseq xHYB Long Read Panels - AInvest
What drives Pacific Biosciences of California Inc. stock priceRapid capital growth - jammulinksnews.com
PacBio (PACB) Collaborates with Qiagen for Enhanced Genomic Insi - GuruFocus
QIAGEN launches long-read sequencing panels for complex genomic regions By Investing.com - Investing.com Canada
PACB Stock Rally: Bullish Signs or Temporary Spike? - StocksToTrade
Published on: 2025-07-22 17:54:31 - jammulinksnews.com
DNA Sequencing Leader PacBio Sets Q2 2025 Earnings Release Date: What Analysts Are Watching - Stock Titan
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pacific Biosciences Of California Inc Stock (PACB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HENRY CHRISTIAN O | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
12,497 |
17,583 |
2,225,357 |
| Van Oene Mark | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
6,486 |
9,126 |
1,497,695 |
| Farmer Michele | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
2,973 |
4,183 |
184,619 |
0.14%
10.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):